these results demonstrate that the very low or undetectable levels of nk activity present in pbmc and e+ cell populations from previously untreated patients with b-cll , regardless of the clinical stage of the disease , can be modified by systemic therapy with alkylating agents .
C1321301
pbmc
C0007634
cell